Table 1.
Demographics and clinical characteristics of the participants.
| SCZ |
Healthy control |
Total |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean ± SD |
F or χ2 | P | Mean ± SD |
F or χ2 | P | Mean ± SD |
F or χ2 | P | ||||
| AA | CA/CC | AA | CA/CC | AA | CA/CC | |||||||
| Age (years) | 27.44 ± 6.81 | 28.24 ± 8.78 | 0.11 | 0.74 | 26.84 ± 4.57 | 27.20 ± 6.11 | 0.91 | 0.76 | 27.06 ± 5.42 | 27.47 ± 6.88 | 0.14 | 0.71 |
| Gender (male/female) | 18 (15/3) | 34 (30/4) | 0.24 | 0.68 | 32 (25/7) | 96 (74/22) | 0.02 | 1.00 | 50 (40/10) | 130 (104/26) | 0.00 | 1.00 |
| Education (years) | 12.44 ± 2.85 | 13.00 ± 3.19 | 0.38 | 0.54 | 13.62 ± 2.64 | 12.59 ± 3.19 | 2.72 | 0.10 | 13.20 ± 2.75 | 12.70 ± 3.18 | 0.96 | 0.33 |
| PANSS positive score | 19.33 ± 11.12 | 17.91 ± 10.28 | 0.21 | 0.65 | NA | NA | NA | NA | NA | NA | NA | NA |
| PANSS negative score | 16.28 ± 10.49 | 17.62 ± 9.96 | 0.21 | 0.65 | NA | NA | NA | NA | NA | NA | NA | NA |
| PANSS total score | 62.89 ± 38.88 | 68.35 ± 33.99 | 0.28 | 0.60 | NA | NA | NA | NA | NA | NA | NA | NA |
| Number of episodes | 2.72 ± 1.56 | 2.85 ± 1.51 | 0.09 | 0.76 | NA | NA | NA | NA | NA | NA | NA | NA |
| Age of onset (years) | 20.88 ± 3.99 | 21.74 ± 4.48 | 0.46 | 0.49 | NA | NA | NA | NA | NA | NA | NA | NA |
| Illness duration (months) | 72.66 ± 59.14 | 70.28 ± 71.29 | 0.02 | 0.90 | NA | NA | NA | NA | NA | NA | NA | NA |
| Medication dosage (mg/day)a | 310.72 ± 273.52 | 224.88 ± 172.53 | 1.92 | 0.17 | NA | NA | NA | NA | NA | NA | NA | NA |
a
Chlorpromazine equivalents.